PIK3CD and cancer: The analysis demonstrated that increased LINC01224 expression was associated with decreased drug sensitivity of cancer cells to ARRY-162, Trametinib, Cobimetinib, Selumetinib, Dabrafenib, and Vemurafenib, whereas increased PIK3CD-AS2 expression was associated with increased drug resistance of cancer cells to 6-Mercaptopurine, Copanlisib, Dasatinib, and Pipamperone.